# Durvalumab as Consolidation for Patients LS-SCLC

> **NCT07055581** · PHASE2 · RECRUITING · sponsor: **Qian Chu** · enrollment: 100 (estimated)

## Conditions studied

- Small Cell Lung Cancer Limited Stage

## Interventions

- **DRUG:** Induction Durvalumab +etoposide/platinum +Radiochemotherapy+ durvalumab maintenance

## Key facts

- **NCT ID:** NCT07055581
- **Lead sponsor:** Qian Chu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-24
- **Primary completion:** 2029-07-31
- **Final completion:** 2029-07-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07055581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07055581, "Durvalumab as Consolidation for Patients LS-SCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07055581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*